迟发性运动障碍治疗市场 - 按药物（Deutetrabenazine、Valbenazine）、剂型（胶囊、片剂）、配销通路（医院药房、药房和零售药房、线上药房） - 全球预测（2024 - 2032）

2024年至2032年，全球迟发性运动障碍治疗市场的复合年增长率将超过7.1%，原因是需要长期抗精神病药物治疗的慢性精神疾病的盛行率不断增加，从而增加了迟发性运动障碍的发生率。神经精神病学研究的进步使人们更好地理解和认识了这种疾病，促进了更有针对性和更有效的治疗方案的发展。

重点是开发新的药物类别和配方，以更好地管理症状并减少副作用。这将改善患者的治疗效果并解决未满足的医疗需求，以刺激市场扩张。药物机制和给药方法的不断创新正在促进迟发性运动障碍治疗市场的成长。举个例子，梯瓦製药公司宣布在 2024 年初启动一项新的 3 期临床试验，重点研究一种旨在减轻迟发性运动障碍症状的新型化合物。该研究预计将深入了解该药物的功效和安全性，并有可能为治疗领域设定新标准。

整个迟发性运动障碍治疗产业根据药物、剂型、配销通路和地区进行分类。

丁苯那嗪细分市场在预测期内将录得值得称讚的复合年增长率，这归因于人们越来越认识到其有效解决治疗抗药性病例的潜力。重点在于优化治疗结果、减少副作用，并为对传统治疗反应不佳的患者提供更好的治疗选择。医疗保健提供者和患者对丁苯那嗪优点的认识的提高对其采用产生了积极影响。此外，良好的临床试验结果和临床指南的支持也有利于该细分市场的成长。

由于人们越来越青睐方便且患者友善的剂型，胶囊细分市场将在 2032 年获得有前景的迟发性运动障碍治疗市场份额。胶囊剂量准确且易于摄入，从而提高患者的依从性和对治疗方案的依从性。此外，掩盖令人不愉悦的味道和气味的能力使胶囊成为患者更容易接受的选择。随着医疗保健提供者和患者寻求更易于管理和更有效的治疗解决方案，胶囊细分市场的份额将会激增。

到 2032 年，欧洲迟发性运动障碍治疗市场将呈现显着的复合年增长率，因为人们对该疾病的认识不断提高，诊断能力不断提高，从而能够更好地识别疾病。该地区先进的医疗基础设施支持先进的治疗方案，同时增加对神经病学研究的投资提高了治疗的可用性。此外，欧洲人口老化和慢性病盛行率上升导致对有效 TD 管理的需求不断增长。有利的医疗保健政策和报销策略有助于获得更新、更有效的治疗方法，推动整个欧洲的市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 迟发性运动障碍盛行率上升
    • 提高对迟发性运动障碍的认识与教育
    • 研发活动数量不断增加
    • 治疗学不断进步
  • 产业陷阱与挑战
    • 治疗费用高
    • 严格的监管审批
• 成长潜力分析
• 监管环境
• 管道分析
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪錶板

第 5 章：市场估计与预测：按药品分类，2021 - 2032 年

• 主要趋势
• 丁苯那嗪
• 缬苯那嗪
• 其他药品

第 6 章：市场估计与预测：按剂型，2021 - 2032

• 主要趋势
• 胶囊
• 平板电脑

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 药局和零售药局
• 网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• H. Lundbeck A/S
• Luye Pharma Group
• Mitsubishi Tanabe Pharma Corporation
• Neurocrine Biosciences Inc.
• SteriMax Inc.
• SOM Biotech
• Teva Neuroscience, Inc.

Global Tardive Dyskinesia Therapeutics Market will showcase over 7.1% CAGR from 2024 to 2032, owing to the growing prevalence of chronic psychiatric conditions requiring long-term antipsychotic treatment, which increases the incidence of tardive dyskinesia. Advances in neuropsychiatric research have led to better understanding and recognition of the disorder, prompting the development of more targeted and effective therapeutic options.

There is focus on developing new drug classes and formulations that offer better management of symptoms and reduced side effects. This will improve patient outcomes and addresses unmet medical needs, stimulating market expansion. Continuous innovation in drug mechanisms and delivery methods is contributing to tardive dyskinesia therapeutics market growth. Quoting an instance, Teva Pharmaceuticals announced the initiation of a new Phase 3 clinical trial in early 2024, focusing on a novel compound aimed at reducing tardive dyskinesia symptoms. The study is expected to provide insights into the drug's efficacy and safety, potentially setting a new standard in the treatment landscape.

The overall tardive dyskinesia therapeutics industry is sorted based on drug, dosage form, distribution channel, and region.

The Deutetrabenazine segment will record a commendable CAGR during the forecast period, attributable to the growing recognition of its potential to address treatment-resistant cases effectively. There is emphasis on optimizing therapeutic outcomes, reducing side effects, and offering improved management options for patients who have not responded well to conventional treatments. Enhanced awareness among healthcare providers and patients about the advantages of deutetrabenazine positively influences its adoption. Additionally, favorable clinical trial results and support from clinical guidelines are favoring the segment growth.

The capsules segment will acquire a promising tardive dyskinesia therapeutics market share by 2032, owing to the increased preference for convenient and patient-friendly dosage forms. Capsules offer accurate dosing and ease of ingestion, which improves patient compliance and adherence to treatment regimens. Additionally, the ability to mask unpleasant tastes and odors makes capsules a more acceptable option for patients. As healthcare providers and patients seek more manageable and effective treatment solutions, the capsules segment share will surge.

Europe tardive dyskinesia therapeutics market will evince a notable CAGR through 2032, because of heightened awareness about the condition, and improved diagnostic capabilities leading to better disease identification. The region's progressive healthcare infrastructure supports advanced treatment options while increasing investments in neurology research enhance therapeutic availability. Furthermore, Europe's aging population and rising prevalence of chronic conditions contribute to the growing need for effective TD management. Favorable healthcare policies and reimbursement strategies facilitate access to newer and more effective therapies, driving market growth across Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of tardive dyskinesia
    • 3.2.1.2 Increased awareness and education about tardive dyskinesia
    • 3.2.1.3 Growing number of research and development activities
    • 3.2.1.4 Increasing advancement in therapeutics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Stringent regulatory approvals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Deutetrabenazine
• 5.3 Valbenazine
• 5.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Capsules
• 6.3 Tablets

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Drug store & retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 The Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 H. Lundbeck A/S
• 9.2 Luye Pharma Group
• 9.3 Mitsubishi Tanabe Pharma Corporation
• 9.4 Neurocrine Biosciences Inc.
• 9.5 SteriMax Inc.
• 9.6 SOM Biotech
• 9.7 Teva Neuroscience, Inc.